|
KMID : 1216720100020020102
|
|
Korean Journal of Gynecologic Endocrinology
2010 Volume.2 No. 2 p.102 ~ p.109
|
|
|
The Relationship between Wnt Signaling Pathway Gene Polymorphisms and Changes in Production of Osteoprotegerin and Soluble Receptor Activator of NF-kB by Whole Blood Cells after Hormone Therapy
|
|
Kim Jung-Gu
Kim Hoon
Ku Seung-Yup
Suh Chang-Suk
Kim Seok-Hyun
Choi Young-Min
|
|
|
Abstract
|
|
|
|
Objective: To investigate the relationship between single nucleotide polymorphism (SNP)s in Wnt signal pathway genes, and production of osteoprotegerin (OPG) and soluble receptor activator of NF-κB ligand (sRANKL) by whole blood cells after hormone therapy (HT) in postmenopausal Korean women. Methods: Low density lipoprotein receptor-related protein (LRP) 5 c.266A>G and c.3893C>T, frizzled (FZD) 6 c.1033A>C, axin II c.148C>T, T cell factor (Tcf) 1 c.766 G>A, and adenomatous polyposis coli (APC) c.5465T> A polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCRRFLP), direct sequencing, and Taqman assay in 72 postmenopausal Korean women receiving estrogen-progestogen therapy. The production of OPG and sRANKL by lipopolysaccharide-stimulated whole blood cells before and after 6 months of HT was also measured. Results: Changes in the production of OPG and sRANKL by lipopolysaccharide-stimulated whole blood cells, and in ratios of sRANKL×1,000/OPG after 6 months of HT were not different according to SNPs in Wnt signal pathway genes measured. There were also no significant differences in changes in the production of OPG and sRANKL, and in ratios of sRANKL×1,000/OPG among combined genotypes of LRP5 c.266A>G and c.3893C>T polymorphisms after HT. Conclusion: LRP5 c.266A>G and c.3893C>T, FZD6 c.1033A>C, axinII c.148C>T, Tcf1 c.766G>A, and APC c.5465T>A polymorphisms are not related with changes in the production of OPG and sRANKL by lipopolysaccharide- stimulated whole blood cells after HT.
|
|
|
KEYWORD
|
|
|
Hormone therapy, Osteoprotegerin, Polymorphism, Receptor activator of nuclear factor-kB ligand, Whole blood cell
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|